Sugi Predict

Sugi Predict / Compounds / SCHEMBL2034437

SCHEMBL2034437

SCHEMBL2034437

CC(C)(C)OC(=O)N1CC[C@H](NS(C)(=O)=O)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 1/20 0.52
▸ BRD4 O60885 1/20 0.48
▸ USP30 Q70CQ3 5/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ HSD11B1 P28845 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ HPGD P15428 1/20 0.44
▸ GPR119 Q8TDV5 2/20 0.44
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ EPHX2 P34913 1/20 0.43
▸ STS P08842 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1860749 1.00 EPHX1 (0.52) EPHX1BRD4USP30CYP2C9HSD11B1
SCHEMBL22680077 1.00 EPHX1 (0.52) EPHX1BRD4USP30CYP2C9HSD11B1
SCHEMBL21664372 0.92 EPHX1 (0.50) EPHX1BRD4USP30ALDH1A1MAPT
SCHEMBL30636984 0.92 EPHX1 (0.50) EPHX1BRD4USP30ALDH1A1MAPT
SCHEMBL716519 0.91 EPHX1 (0.58) EPHX1ALDH1A1NPC1MAPTMAPK1
SCHEMBL15174329 0.88 NR1H2 (0.46) EPHX1BRD4ALDH1A1HPGDGPR119
SCHEMBL15084804 0.87 EPHX1 (0.51) EPHX1BRD4USP30CYP2C9HSD11B1
SCHEMBL10177852 0.87 EPHX1 (0.49) EPHX1ALDH1A1NPC1MAPTMAPK1
SCHEMBL10177856 0.87 EPHX1 (0.49) EPHX1ALDH1A1NPC1MAPTMAPK1
SCHEMBL31722057 0.86 EPHX1 (0.60) EPHX1BRD4ALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025229494-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-11-06 — — WO disclosed
US-20250250230-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-08-07 — — US disclosed
EP-4508027-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2025-02-19 — — EP disclosed
CN-115244037-B Substituted triazinones as thyroid hormone receptor agonists 诚益生物(美国)公司 2024-10-25 — — CN disclosed
WO-2023199091-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-19 — — WO disclosed
US-11780825-B2 Thyroid hormone receptor agonists and use thereof ECCOGENE (SHANGHAI) CO., LTD. (CN) 2023-10-10 — — US disclosed
US-11780825-B2 Thyroid hormone receptor agonists and use thereof ECCOGENE (SHANGHAI) CO., LTD. (CN) 2023-10-10 — — US disclosed
CN-115244037-A Substituted triazinones as thyroid hormone receptor agonists 上海诚益生物科技有限公司 2022-10-25 — — CN disclosed
US-11339165-B2 Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) Janssen Sciences Ireland Unlimited Company (IE) 2022-05-24 — — US disclosed
US-11339165-B2 Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) Janssen Sciences Ireland Unlimited Company (IE) 2022-05-24 — — US disclosed
US-20210230146-A1 THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF ECCOGENE INC. 2021-07-29 — — US disclosed
US-20200361942-A1 PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) Janssen Sciences Ireland Unlimited Company (IE) 2020-11-19 — — US disclosed
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 — — US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 — — US disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250230-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NPY2R EPHX1 1023/4885BRD4 541/4885USP30 4016/4885
US-20200361942-A1 PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) RRP15, MAVS, ACE EPHX1 2081/4885BRD4 929/4885USP30 4814/4885
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS PIK3R1, PIK3R3, PIK3R2 EPHX1 3007/4885BRD4 874/4885USP30 1022/4885
US-20210230146-A1 THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF TSHR, THRA, THRB EPHX1 2992/4885BRD4 4160/4885USP30 1945/4885
US-11339165-B2 Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) RRP15, MAVS, ACE EPHX1 2081/4885BRD4 929/4885USP30 4814/4885
US-11780825-B2 Thyroid hormone receptor agonists and use thereof TSHR, THRA, THRB EPHX1 2992/4885BRD4 4160/4885USP30 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.